Methodological issue in prediction model for nodal disease among patients with lung cancer
Publication date: Available online 18 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Soodeh Shahsavari
In conclusion, protection of the thiol disulfide homeostasis is of great importance for the human being. Evidence achieved so far has proposed that thiol-disulfide homeostasis is an important issue needs to elucidate wholly. PMID: 32233181 [PubMed - as supplied by publisher]
Publication date: July 2020Source: Materials Science and Engineering: C, Volume 112Author(s): Nitin Gupta, Stuti Bhagat, Mandeep Singh, Ashok Kumar Jangid, Vipul Bansal, Sanjay Singh, Deep Pooja, Hitesh Kulhari
CONCLUSIONS: According to the indicators of incidence and mortality of lung cancer in Split-Dalmatia County, this malignant neoplasm should occupy a high place within County public health priorities measures of prevention programme, targeting risk factors responsible for their formation. PMID: 32228819 [PubMed - in process]
CONCLUSION: The evaluated studies show that continued smoking after lung cancer diagnosis is related to poor prognosis, reduced survival, risk of second primary malignancies, and increased cancer recurrence. Of particular importance is the deterioration in the quality of life and an increased incidence of the adverse drug reactions in smokers. The patient's cigarette smoking history should be considered carefully and smoking cessation must be taken into account. PMID: 32228818 [PubMed - in process]
The U.S. Environmental Protection Agency released an asbestos draft risk evaluation Monday that found serious health dangers to workers in the chloralkali industry, the country’s last remaining user of raw asbestos. There is an “unreasonable risk to workers, occupational non-users, consumers and bystanders” the EPA found when evaluating several asbestos products still being imported and used today. The draft risk evaluation was an initial review of asbestos by the EPA under the amended Toxic Substances Control Act (TSCA). “It is being disseminated for peer review purposes and is not final,” an...
Authors: van Zandwijk N, Reid G, Frank AL Abstract Introduction: Asbestos, the most frequent cause of occupational cancer, continues to be consumed on a massive scale, with millions of people exposed on a daily basis. This review explains why we have failed in curtailing the silent epidemic of asbestos-related disease and why the numbers of asbestos victims are likely to remain high. Emerging and developed countries have to be reminded that asbestos exposure has yet to become a problem of the past. The worldwide spread of asbestos, followed by the surge of asbestos-related cancers, resembles the lung cancer epidemi...
Authors: Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S Abstract Introduction: Gene fusions are strong driver alterations in various cancers, increasingly diagnosed with multiple testing techniques. ROS1 fusions can be found in 1-2% of non-small cell lung cancer (NSCLC) and several tyrosine kinase inhibitors (TKIs) have been tested in this oncogene-driven disease. NTRK fusions are characteristic of a few rare types of cancer, also infrequently seen in some common cancers including NSCLC. Entrectinib is a newer ROS1 and NTRK inhibitor developed across different tumour types harbouring rearran...
Conclusions: With proteomic approaches, we have discovered neutrophil defensins as additional prospective biomarkers for an anti-PD-(L)1 immunotherapy response. Thereby, we also demonstrated that the neutrophil defensins contribute in the activation of the immune response towards cancer cells, which could provide a new lead towards an anticancer therapy.
Immune checkpoint inhibitors (ICIs) have become the standard treatment in non-small cell lung cancer (NSCLC). Four phase III randomized trials have shown that ICIs such as nivolumab, atezolizumab and pembrolizumab significantly improve overall survival (OS) and quality of life (QoL) when compared with docetaxel in patients who have progressed on prior treatment with a platinum doublet [1,2,3,4]. Programmed death-ligand 1 (PD-L1) expression has been the main predictive biomarker explored for response to anti-PD-1/L1 immunotherapy.